Background Actinic keratoses (AKs) in solid organ transplant recipients (OTRs) are difficult-to-treat premalignancies and comparison of topical therapies is therefore warranted.
• Patients experienced higher levels of pain sensation and more intense, but shorterlasting, inflammatory skin reactions for PDT compared with IMIQ.
• Patients had an equal preference for both PDT and IMIQ treatments.
Squamous cell carcinomas (SCCs) occur at 65-100 times higher incidence in immunosuppressed solid organ transplant recipients (OTRs) than in the background population and account for approximately 5% of mortality causes. 1, 2 As SCCs commonly develop from actinic keratoses (AKs) in field-cancerized skin, topical therapies that effectively target visible and subclinical lesions are essential to prevent malignant transformation. [3] [4] [5] OTRs experience lower AK response rates than immunocompetent patients. 6 However, efficacy rates of topical therapies are generally reported only to a limited extent in the transplant recipient population. Photodynamic therapy (PDT) with methyl aminolaevulinate (MAL) or 5-aminolaevulinic acid is considered to be safe and is the most extensively documented treatment for AKs in OTRs, [6] [7] [8] [9] [10] [11] [12] [13] [14] followed by imiquimod (IMIQ), [15] [16] [17] [18] [19] while only a few studies have assessed 5-fluoruracil and diclofenac for AK clearance. 8, 20 PDT and IMIQ utilize different mechanisms of action; PDT induces photochemical apoptosis of dysplastic cells by reactive oxygen species, whereas IMIQ modulates the skin's cellular immune response to induce an inflammatory reaction. Although studies have found IMIQ to be safe for treating skin areas up to 60 cm 2 , 15, 18, 19, 21 concern remains about whether IMIQ can stimulate a systemic immune reaction and potentially affect graft function, as reported in one renal OTR. 22 In contrast,
PDT is safe in OTRs and is not associated with potential graft damage, even when treating large skin areas. 5 The chronic nature of AKs in immunosuppressed OTRs necessitates repetitive treatments, often applying a rotating regimen between available field therapies and alternating between different treatment modalities. However, no direct comparison of some of the most widely used treatments, including PDT and IMIQ, has been performed so far.
The aim of this study was to compare efficacy, local skin reactions and the safety of MAL-PDT and IMIQ in an intraindividual, randomized study with blinded outcome evaluation.
Materials and methods

Inclusion criteria and patients
OTRs with clinically diagnosed AKs on the face, scalp, dorsal hands or forearms were recruited from the departments of Dermatology at Bispebjerg Hospital and Sahlgrenska Hospital. Study treatments were carried out from February 2010 to November 2014. Patients were required to have two comparable skin areas within the same anatomical localization, each area measuring 40 cm 2 and having at least two grade-II or grade-III AKs. Inclusion criteria were age > 18 years, stable graft function, Fitzpatrick skin types I-III and signed written informed consent. Exclusion criteria were porphyria, allergy to MAL or IMIQ cream, infiltrating tumours or AK treatment of study areas within the previous 4 weeks. Lactating or pregnant women and patients with conditions associated with a risk of poor compliance were not included. The patients were informed about the available safety data on both treatments. The study was approved by the national medicines agencies (EudraCT 2008-002233-11), local ethics committees (H-42012-063 Denmark and D439-10 Sweden) and was conducted in accordance with the Declaration of Helsinki.
Study design
All patients received parallel or split-side treatment with IMIQ and PDT. Both study areas in each patient were located in the same anatomical region. All AK lesions within each study area were included for study treatments. Each lesion was mapped on a template, numbered and classified by thickness into the following grades: I, mild (slightly palpable); II, moderate (moderately thick) and III, severe (very thick). 23 Next, treatment areas were randomized to PDT or IMIQ. Randomization was performed in three blocks of 10 patients and one block of five patients using a computer-generated sequence. Allocation was concealed in opaque, sequentially numbered, sealed envelopes. Figure 1 illustrates study visits. All patients received one PDT and one IMIQ treatment at baseline and were seen at 1, 2 and 3 months after baseline. The study treatments followed the licensed European Medicines Agency treatment regimens. Hence, in cases of nonresponding AKs, IMIQ treatment was repeated 2 months after baseline and PDT was repeated 3 months after baseline (Fig. 1) . Patients with total clearance of AKs from one study treatment had final evaluation after PDT at 3 months from baseline and after IMIQ at 4 months from baseline. In study areas receiving two treatment sessions, efficacy was assessed at 6 months after baseline, corresponding to 3 months after finalizing the second PDT and IMIQ treatment (Fig. 1) .
Interventions
In IMIQ study areas, IMIQ cream (50 g Aldara, 5% IMIQ, Solna, Sweden) was applied to the entire treatment area prior to sleeping hours and left for approximately 6-10 h. One IMIQ treatment session included three applications per week for 4 weeks. Application was demonstrated to the patients at baseline and the patients subsequently self-administered IMIQ doses.
In PDT study areas, a gentle curettage to remove crusts and scales was performed on the entire area, avoiding any bleeding, in accordance with standard PDT procedures. MAL cream (Metvix â cream 16%, Galderma SA, Lausanne, Switzerland)
was then applied at 0Á5-mm layer thickness and occluded under light-impermeable dressing. After 3 h, any remaining MAL cream was wiped off and the treatment area was illuminated with a red light-emitting diode (LED) (Aktilite CL128, Galderma, Biot -Sophia Antipolis, France) at 634 nm, 68 mWÁcm À2 irradiance with a total light dose of 37 JÁcm À2 .
Outcome measures
The primary outcome measure was blindly evaluated complete response (CR), defined as the number of AK lesions at baseline minus the number of AK lesions at the 3-month and 6-month evaluation divided by the total number of treated lesions in each study area. Secondary outcomes were: (i) new AK lesions in each study area; (ii) skin reactions; (iii) pain or discomfort during PDT and IMIQ treatment; (iv) laboratory values; (v) cosmetic outcome; and (vi) treatment preference. All investigator evaluations were performed by blinded assessors.
Lesion response
Treatment areas were identified from the baseline template and served as a map for lesion response from baseline and identifying new lesions. AKs were classified as CR upon the complete disappearance of the lesion, although mild erythema might remain.
Clinical assessments
The patients assessed skin reactions daily in each study area using a questionnaire (diary) for the separate evaluation of pain/discomfort and overall severity of inflammatory skin reactions (4-point scale) in each treatment area. Diaries were completed until skin reactions in study areas were completely resolved 1 month after PDT and until 2 months after the initiation of IMIQ treatment. Pain assessments in the diary and during LED illumination were quantified using a numerical rating scale ranging from 0 to 10 (0 = no pain, 10 = worst pain imaginable). At final follow-up (FU), blinded investigators evaluated pigmentary changes and scarring (4-point scale) and also assessed cosmetic outcomes as poor, acceptable, good or excellent.
Safety
Laboratory values were monitored in all patients at baseline and at 1, 2 and 3 months. All patients were monitored for changes in haemoglobin, creatinine, C-reactive protein and provided a urine-test strip for proteinuria. Liver transaminases (alanine aminotransferase and aspartate aminotransaminase) were also assessed for liver transplant recipients and white blood cell counts were assessed for lung transplant recipients. Changes in immunosuppressive regimens were registered throughout the study.
Statistics
Sample size calculations were based on a minimal relevant difference of 12% with a 20% SD difference in response, requiring 35 patients receiving split-side treatment for inclusion at an 80% power and 5% significance level. Median and range were used for descriptive data. Differences between treatment groups in terms of AK response rates, skin reactions, pain intensities and cosmetic response were compared using Wilcoxon signed-rank test for paired nonparametric data. Baseline AK distribution, skin reactions and pain intensities were also compared. P < 0Á05 were considered significant. All statistics were performed using SPSS Statistics version 22 (IBM, Armonk, NY, U.S.A.).
Results
Patients
A total of 35 patients (22 men and 13 women) were included from Bispebjerg Hospital (n = 20) and Sahlgrenska Hospital (n = 15). Overall, 33 patients completed all study visits. Two patients withdrew informed consent at the 2-month visit, one owing to a leg fracture and one for personal reasons. The patients had a mean age of 63 years (range 45-79) and had Fitzpatrick skin type I (n = 9), II (n = 22) or III (n = 4). The median time since transplantation was 10 years (range 4-32) and graft organs included kidney transplants (n = 28), lung transplants (n = 3) and liver transplants (n = 4). The patients received immunosuppression with tacrolimus (n = 12), ciclosporin (n = 14), azathioprine (n = 12), mycophenolate mofetil (n = 15), mechanistic target of rapamycin inhibitor (n = 8) and low-dose steroids (n = 31) in a triple (n = 24) or double (n = 9) immunosuppressive regimen. At baseline, the patients had a total of 572 AKs (grade I-III) with median 8Á3 AKs in each treatment area (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Study areas comprised the face or scalp (n = 19), dorsal forearms (n = 6) and dorsal hands (n = 10) ( Table 1 ). Table 1 summarizes the efficacy of PDT and IMIQ. Most patients required two treatment sessions in both PDT (n = 25) and IMIQ treatment areas (n = 29); however, one treatment cleared all AKs in seven areas treated with PDT and in four areas treated with IMIQ. After one treatment, PDT obtained a median overall CR of 66% (range 20-100%, 3-month FU), and IMIQ achieved a median CR of 49% (range 0-100%, 1-month FU) (P < 0Á001).
Efficacy evaluation
After two treatment sessions, overall CR rates were higher after PDT (median 78%, range 50-100%) than IMIQ (median 61%, range 33-100%) at 3-month FU (P < 0Á01) ( Table 1 and Fig. 2 ). Additionally, 10 study areas had complete AK clearance after PDT and eight study areas had complete AK clearance after IMIQ. According to AK grade, PDT was more effective than IMIQ for thin grade-I AKs (median CR 82% vs. 66%, P < 0Á01) and for keratotic grade-II and grade-III AKs (median CR 33% vs. 25%, P = 0Á04). Furthermore, patients developed more new AKs in areas treated with IMIQ (1Á5 AKs, range 0-6) than in areas treated with PDT (0Á7 AKs, range 0-3) (P = 0Á04).
Overall, CR rates increased from 66% to 78% (P = 0Á03) when patients received two PDT treatment sessions rather than one and from 49% to 61% and when patients received two treatment sessions with IMIQ (P = 0Á02).
Skin reactions and pain sensations
Patient-registered local skin reactions varied for PDT and IMIQ treatments, both with regard to intensity, duration and time to peak reactions (Fig. 2) . Thus, patients achieved more intense skin reactions in the area treated with PDT (median 2Á8, range 1-4) compared with the IMIQ-treated area (median 1Á7, range 0-4) (P < 0Á001), with peak reactions occurring 1-4 days after PDT and 3-4 weeks after commencing IMIQ treatment. Overall, skin reactions persisted longer in skin treated with IMIQ (median 18 days, range 5-41) than in PDTtreated skin (median 10 days, range 7-18) (P < 0Á001).
Patients experienced higher levels of pain sensation during PDT than during IMIQ treatment (P < 0Á001). Hence, PDT illumination induced moderate pain intensities (median 5Á6, range 3-9) that resolved within 3 days, whereas patients recorded no pain (visual analogue scale = 0, n = 29) or slight pain/discomfort of 1-3 (n = 6) lasting up to 5 days during IMIQ treatment. Skin reactions and pain intensities did not differ between the first and second PDT or IMIQ treatment sessions. No patients developed hyperpigmentation, hypopigmentation or textural changes. Patients reported 'excellent' or 'good' cosmetic outcomes in both PDT and IMIQ treatment areas (PDT: 'excellent' n = 9, 'good' n = 16 and 'fair' n = 10; IMIQ: excellent, n = 11, good n = 15 and fair n = 6; P = 0Á41). Investigators also assessed similar cosmetic outcomes following PDT and IMIQ treatment (PDT: 'excellent' n = 19, 'good' n = 11 and 'fair' n = 5; IMIQ 'excellent' n = 18, 'good' n = 11 and 'fair' n = 6; P = 0Á37). Patients expressed a similar preference for both treatments; 19 patients preferred PDT and 16 patients preferred IMIQ (P = 0Á47).
Safety
We observed minor transient fluctuations in laboratory levels during the study period. Patients had no substantial adjustments of immunosuppressive treatment dosage and no patients changed immunosuppressive treatment regimen (Table S1 ; see Supporting Information).
Discussion
This is the first intrapatient comparison of the efficacy and tolerability of PDT and IMIQ for the treatment of AKs in OTRs. We found that PDT cleared AKs in OTRs more effectively compared with IMIQ, but was also associated with higher levels of pain sensation and more intense inflammatory skin reactions. Patients had an equal preference for both treatments, which indicates that AK therapies should ideally be adjusted to individual patient-related factors. Hence, some patients prefer in-office treatments associated with a shorter, more intense inflammatory response, whereas other patients prefer homebased treatments with longer treatment duration and longer persistence of skin reactions.
In OTRs, PDT is currently the best-documented field-directed treatment for AKs. In accordance with our results, studies reported 55-60% CR following one PDT session and 68-90% CR after two PDT treatment sessions. [6] [7] [8] [9] [10] [11] 18 Previous IMIQ studies applied longer treatment periods with three applications per week for 16 consecutive weeks, resulting in CR rates of 62-68% CR at 8 weeks FU. 18, 19 In this study, we applied IMIQ according to the treatment regimen of 4 weeks that has been approved by the European Medicines Agency, repeated after 1 month for cases with remaining AKs. Therefore, two IMIQ sessions were required for the majority of patients as IMIQ achieved 49% CR at 1 month after a single session, which increased to 61% CR at 3 months after two IMIQ sessions. Compared with previous studies, our results may indicate that efficacy rates from 8 weeks and 16 weeks of IMIQ treatment can be comparable for immunosuppressed solid OTRs. In accordance with previous studies, thin grade-I AKs responded better to PDT and IMIQ treatments than thicker grade-II and grade-III AKs.
In immunocompetent patients with AKs, direct comparisons of PDT and IMIQ have shown slightly higher CR rates of 65-72% after PDT compared with 56-59% after IMIQ at 6-month FU or 12-month FU. 24, 25 PDT and IMIQ exert different mechanisms of action in AK treatment. In PDT, photosensitizing protoporphyrin IX accumulates in dysplastic lesions and upon activation by light, generates reactive oxygen species that induce apoptosis, vascular shutdown and subsequent tissue inflammation. 26 IMIQ is a Toll-like receptor 7 agonist that modifies the innate immune response by stimulating the migration of dendritic cells into the skin and inducing cytokine production of interferon (IFN)-a, IFN-c, tumour necrosis factor-a and interleukin (IL)-2, IL-6, IL-8 and IL-12. 27, 28 Interestingly, the immunosuppressive drugs ciclosporin A and tacrolimus have, under certain circumstances, been shown to inhibit Toll-like receptor signalling, although the clinical relevance has not been investigated. Thus, PDT is based on a photochemical reaction, whereas IMIQ relies on a patient-generated immune response that may be impaired in immunosuppressed OTRs. 29 Although topically applied, concern has been raised about whether IMIQ can potentially initiate a systemic immune response and impair graft function. Accordingly, the European Medicines Agency advises IMIQ treatment in skin areas smaller than 60 cm 2 in OTRs, whereas the U.S. Food and Drug
Administration does not recommend IMIQ for use in transplant recipients. We closely monitored laboratory values and found no significant changes during or after the study treatments with 50 mg IMIQ (one sachet) three times per week for 4 weeks as reported in previous studies. 19, 30 However, because IMIQ is considered an off-label therapy in OTRs, it is mandatory to balance the potential risk of graft rejection compared with safer AK treatments such as PDT before treatment is initiated. This study assessed the efficacy of PDT and IMIQ for the treatment of AKs in a Scandinavian OTR population and has a number of important strengths, including intraindividual study design, blinded efficacy assessment and consistent treatment and FU times.
One limitation of this study is the potential systemic effect of IMIQ on PDT treatment sites, although previously quantified systemic IMIQ concentrations were low. In the majority of patients, untreated skin was separated into IMIQ and PDT study areas to avoid interference between study treatments. Hence, a potential systemic effect of IMIQ on the PDT treatment site, and vice versa, cannot be ruled out, but is considered to be of limited impact in this study setup. Also, a longer FU would have been preferable to ensure longer-term response rates. Our patients had a larger proportion of grade-I AKs, compared with grade-II and grade-III AKs, which hampers the observed treatment efficacy for hyperkeratotic lesions, but also reflects typical cases in our specialized OTR units. Although two of 35 patients withdrew informed consent at the 2-month visit, our study was powered for a 15% CR difference by 32 patients and, thus, retained statistical significance. Finally, conventional PDT was associated with higher pain reactions than IMIQ. These pain reactions would be significantly reduced by replacing LED illumination with continuous daylight activation of the photoactive protoporphyrin IX. Daylight exposure could potentially increase patient preference for PDT, as several studies have reported that patients experience almost no pain during daylight PDT.
In conclusion, we found that PDT resulted in higher efficacy than IMIQ in relation to AK clearance and the prevention of new lesions when evaluated 3 months after treatment. However, PDT also induced more severe pain and inflammatory reactions. Overall, both treatments were equally preferred by patients and no adverse reactions were observed.
